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Abstract 
Background: Chronic fatigue syndrome (CFS) is considered as a neuroimmunological disease but the etiology 
and pathophysiology is poorly understood. Patients suffer from sustained exhaustion, cognitive impairment and an 
increased sensitivity to pain and sensory stimuli. A subset of patients has frequent respiratory tract infections (RRTI). 
Dysregulation of the sympathetic nervous system and an association with genetic variations in the catechol‑O‑meth‑
yltransferase (COMT) and glucocorticoid receptor genes influencing sympathetic and glucocorticoid metabolism 
were reported in CFS. Here, we analyzed the prevalence of SNPs of COMT and glucocorticoid receptor‑associated 
genes in CFS patients and correlated them to immunoglobulin levels and susceptibility to RRTI.
Methods: We analyzed blood cells of 74 CFS patients and 76 healthy controls for polymorphisms in COMT, FKBP5 
and CRHR1 by allelic discrimination PCR. Serum immunoglobulins were determined by immunoturbidimetric tech‑
nique, cortisol levels by ECLIA.
Results: Contrary to previous reports, we found no difference between CFS patients and healthy controls in the 
prevalence of SNPs for COMT, FKBP5 and CRHR1. In patients with the Met/Met variant of COMT rs4680 we observed 
enhanced cortisol levels providing evidence for its functional relevance. Both enhanced IgE and diminished IgG3 lev‑
els and an increased susceptibility to RRTI were observed in CFS patients with the Met/Met variant. Such an associa‑
tion was not observed in 68 non‑CFS patients with RRTI.
Conclusion: Our results indicate a relationship of COMT polymorphism rs4680 with immune dysregulation in CFS 
providing a potential link for the association between stress and infection susceptibility in CFS.
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Background
Chronic fatigue syndrome (CFS) is a severe disease char-
acterized by persistent exhaustion, cognitive dysfunctions 
and flu-like symptoms leading to a substantial reduction 
of quality of life [1]. In a subset of CFS patients there is 
an acute onset of the disease with an infection. Further, a 
subset of patients suffers from recurrent respiratory tract 
infections (RRTI) [2]. A hallmark of CFS is aggravation 
of symptoms by stress [3, 4]. Most patients suffer from 
severe cognitive impairment [5] and increased sensitiv-
ity to pain and sensory stimuli [6]. Dysregulation of auto-
nomic nervous system, an enhanced sensory processing 
in the central nervous system (CNS) and dysfunction of 
the hypothalamic–pituitary–adrenal (HPA) axis are con-
sidered as pathophysiological mechanisms in CFS [7]. 
Enhanced epinephrine and norepinephrine levels were 
found in CFS patients in some [8, 9] but not all studies 
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[10, 11]. Although adrenocorticotropic hormone primar-
ily controls the release of cortisol, also enhanced levels 
of the catecholamine norepinephrine lead to the release 
of cortisol [12]. Diminished and enhanced cortisol lev-
els were reported in CFS patients [13–16]. Further, there 
are studies showing that the regulation of the immune 
function by cortisol and catecholamines is dysregulated 
in CFS patients [10, 17]. In particular, an increased sen-
sitivity of glucocorticoid receptors on lymphocytes is 
proposed to induce a Th2 shift in CFS patients [18, 19]. 
A resistance of T cell function to glucocorticoid and 
β2-adrenergic agonists is reported by others [10].
Presently, few small studies show that CFS is associ-
ated with genetic variations in glucocorticoid receptor 
associated genes and the catechol-O-methyltransferase 
(COMT), an enzyme responsible for the inactivation of 
the catecholamines norepinephrine, epinephrine and 
dopamine by methylation [20]. For the A allele of the 
COMT single nucleotide polymorphism (SNP) rs4680 
at codon 158, resulting in a substitution of Val with Met, 
reduced enzyme activity was shown [21]. Higher fre-
quencies of this variant was shown in CFS patients [22, 
23] and in fibromyalgia [24]. In associative studies an 
increased occurrence of stress-related disorders and neu-
ronal stress response including enhanced cortisol levels 
are published for polymorphisms of the corticotropin-
releasing hormone receptor 1 (CRHR1) and FK506 
binding protein 5 (FKBP5) that interacts with corticoid 
receptor complexes [25–28].
Within our study, we investigated the prevalence of the 
SNPs for COMT rs4680, FKBP5 rs1360780 and CRHR1 
rs12944712 in CFS patients
Patients and methods
Human blood samples
Patients were recruited from the outpatient clinic 
for immunodeficiencies at the Institute for Medical 
Immunology at the Charité Universitätsmedizin Berlin 
between 2011 and 2014. CFS patients submitted were 
not preselected for an infection history or immunode-
ficiency. Patients were of Caucasian ethnicity and diag-
nosed with CFS by fulfilling both Canadian and Fukuda 
criteria [29] and exclusion of other medical or neuro-
logical diseases or depression. Patients with chronic 
systemic steroid or immunosuppressant therapy or a 
diagnosis of primary immunodeficiency were excluded 
from this study. Age and sex-matched healthy con-
trols were recruited from staff. Enhanced susceptibility 
to infection was defined as having a history of at least 
four respiratory tract infections per year or a history of 
severe infections (e.g. pneumonia). Reports on history of 
RRTI were assessed by clinical staff and in two patient 
questionnaires. Data was analyzed by an independent 
reviewer. A further group of patients was included who 
suffered from RRTI but had neither CFS nor immunode-
ficiency. IgG3/4 subclass deficiency was not an exclusion 
criterion for recruitment in this study. Immunoglobulin 
and cortisol levels were analyzed in the routine diag-
nostics laboratory of the Charité, Labor Berlin GmbH 
according to their standards, which require immediate 
transport to the laboratory which is usually below 1  h 
and immediate processing. One sample was used to pre-
pare DNA in our research laboratory for the SNP analy-
ses and DNA quality was checked at 260/280 ratio at the 
nanodrop spectrophotometer. The study was approved 
by the Ethics Committee of Charité Universitätsmedizin 
Berlin in accordance with the 1964 Declaration of Hel-
sinki and its later amendments. All patients and healthy 
controls gave informed consent.
Quantification of immunoglobulins and cortisol
Serum immunoglobulins G and E were determined at 
Labor Berlin GmbH by immunological turbidity test 
(Roche Diagnostics). IgG subclasses were measured 
by immunoturbidimetric technique (The Binding Site) 
and cortisol levels by ECLIA (Cobas 8000, Roche). The 
patient’s serum cortisol was measured between 9 am and 
noon depending on the time of visit at our out-patient 
clinic, but we assume equal distribution of blood drawing 
in all haplotype groups.
SNP analysis
Analysis of the SNPs COMT rs4680 and FKBP5 
rs1360780 was performed according to manufacturer’s 
instruction for the Applied Biosystems 7300/7500/7500 
Fast Real-Time PCR System on 10 ng of genomic DNA. 
Probes were purchased from Applied Biosystems.
Statistical analysis
Statistical data analysis was done using the software SPSS 
Statistics 19. Nonparametric statistical methods were 
used. Continuous variables were expressed as median 
and interquartile range (IQR) if not indicated otherwise. 
Univariate comparisons of two independent groups were 
done using the Mann–Whitney-U test or Chi-Square/
Fisher’s exact test. Confirmatory analyses relative to >2 
groups were performed with the Kruskal–Wallis test fol-
lowed by post hoc testing via Mann–Whitney U test with 
Bonferroni adjustment for multiple testing.
Results
Normal prevalence of polymorphisms for COMT, CRHR1 
and FKBP5 in CFS
First, we analyzed 74 CFS patients and 76 healthy con-
trols for their genotypic and allelic frequencies for the 
SNPs rs4680 for COMT, rs1360780 for FKBP5, and 
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rs12944712 for CRHR1, respectively. Characteristics of 
patients including the Bell score as a level of mental and 
physical disability score from 100 (healthy) to 0 (severe 
disease) are described in Table 1 and distribution of SNPs 
in Table 2. We found no difference between CFS patients 
and controls in the prevalence of the COMT SNP rs4680, 
as well as a similar distribution of FKBP5 SNP rs1360780 
and CRHR1 SNP rs12944712, respectively.
Enhanced cortisol levels associated with the 
hypofunctional Met variant of COMT in CFS
To assess the functional relevance of the SNPs, cortisol 
levels were compared in the groups of CFS patients with 
wild type, heterozygous and homozygous variants. We 
found significantly enhanced cortisol levels in the group 
of CFS patients with the Met/Met allele compared to het-
erozygous and Val/Val allele carrying patients (Fig. 1a). In 
contrast no association was found for cortisol levels and 
SNPs for FKBP5 and CRHR1 (Fig. 1b, c).
SNPs for COMT and FKBP5 are associated 
with immunoglobulin levels in CFS
We had observed that a subset of CFS patients has 
diminished IgG3 and IgG4 levels. Due to the known effect 
of stress and cortisol on immunoglobulin levels [30, 31] 
we therefore correlated the haplotypes for the SNPs for 
COMT, FKBP5 and CRHR1 with the patient’s IgG3 and 
IgG4 levels. Interestingly, we found that the homozygous 
and heterozygous Met variant of COMT rs4680 is associ-
ated with significantly lower IgG3 levels in comparison to 
the homozygous Val genotype (Fig. 2a). No difference for 
the other IgG subclasses as well as IgG, IgM, and IgA was 
observed (data not shown). Oppositely, in patients with 
the FKBP5 SNP rs1360780 wild type variant C/C signifi-
cantly lower levels of IgG4 were found compared to the 
C/T or T/T variant, but no differences in the IgG3 levels 
(Fig. 2b). However, the differences in IgG4 were no longer 
significant after Bonferroni correction. No differences 
were found for the CRHR1 SNP rs12944712 (A/A, A/G, 
G/G) and IgG3/4 levels (Fig. 2c).
Furthermore, it had been shown that norepineph-
rine upregulates IgE production [32]. Thus, we com-
pared COMT subgroups in 54 CFS patients whose IgE 
levels had been determined. Indeed, we found that 
all 10 patients with enhanced IgE levels, defined as 
above 100  U/ml, had hetero- or homozygous Met allele 
(n =  10/44, 22.7  %) whereas no patient (n =  0/10) was 
found in the Val/Val group (Fig. 3). Of those 10 patients 
with elevated IgE, 7 patients had reported allergies.
COMT SNP rs4680 is associated with recurrent infections 
in CFS
As a subset of patients with CFS suffers from suscepti-
bility to infections, we analyzed if COMT SNPs are asso-
ciated with infections. 34 of the 74 patients reported 
to suffer from RRTI. The clinical characteristics of 
the patient cohort are shown in Table  3. 47  % of CFS 
patients with RRTI had received antibiotic treatment 
for RRTI. There was no significant difference in median 
ages, gender or Bell score between the two groups with 
and without RRTI. Interestingly, we found that RRTI are 
Table 1 Characteristics of CFS and control group
na not applicable.
Healthy (n = 76) CFS (n = 74)
Age (years) 40 ± 17 40 ± 9
m/f (%) 43/57 37/63
Bell score na 30 ± 10
Table 2 Association of SNPs with CFS
Allelic discrimination PCR was performed for 74 CFS patients and 76 healthy controls.
SNP n Minor −/− Hetero −/+ Major +/+ Genotypic frequencies (%) Allelic  
frequencies (%)
p value
CRHR1 rs12944712 Met/Met Met/Val Val/Val G A
 Healthy 76 26 38 12 0.34 0.50 0.16 0.59 0.41 0.6189
 CFS 74 27 34 13 0.36 0.46 0.18 0.59 0.41
COMT rs4680 G/G G/A A/A G A
 Healthy 76 18 45 13 0.24 0.59 0.17 0.53 0.47 0.7439
 CFS 74 22 37 15 0.30 0.50 0.20 0.55 0.45
FKBP5 rs1360780 T/T T/C C/C T C
 Healthy 76 8 29 39 0.11 0.38 0.51 0.30 0.70 0.6396
 CFS 74 5 33 36 0.07 0.45 0.49 0.29 0.71
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significantly more frequent in the presence of the Met 
variant of SNP rs4680 for COMT in the CFS patients 
(Fig. 4, p = 0.023). While 31 (91 %) of the 34 patients with 
RRTI had Met, 28 of 40 (70 %) patients without RRTI had 
a Met allele. In contrast, no association was observed for 
the SNPs for FKBP5 rs1360780 and CRHR1 rs12944712. 
To study if this association of Met with RRTI was seen 
in non-CFS patients as well we analyzed an additional 
cohort of 68 patients, who had presented due to RRTI 
at our outpatient clinic (patient characteristics shown in 
Table  3) for the prevalence of these COMT variants. In 
this cohort the frequency of the Met variant was similar 
to CFS patients without RRTI (71 %). Further, neither an 
Fig. 1 Cortisol levels in CFS patients. Serum of 55 CFS patients was analyzed for cortisol levels. Patients were grouped in the respective haplotypes 
of the SNPs for a rs4680 for COMT, b rs1360780 for FKBP5, and c rs12944712 for CRHR1. Statistic analysis was performed with the Kruskal–Wallis 
test followed by post hoc testing via two‑tailed Mann–Whitney U test with Bonferroni adjustment for multiple testing with ***p < 0.00033 (0.001/3 
comparisons) as significant, ns not significant.
Fig. 2 IgG3 and IgG4 levels in CFS patients with COMT, FKBP5, and 
CRHR1 SNP. a Levels of immunoglobulin subclasses IgG3 and IgG4 
were determined in serum of CFS patients and grouped according 
to their genotype for rs4680 for COMT, b rs1360780 for FKBP5, and c 
rs12944712 for CRHR1, respectively. Statistic analysis was performed 
with the Kruskal–Wallis test followed by post hoc testing via two‑
tailed Mann–Whitney U test with Bonferroni adjustment for multiple 
testing with *p < 0.017 (0,05/3 comparisons) as significant.
Fig. 3 Correlation of IgE levels with COMT SNP rs4680. Serum of 54 
CFS patients was analyzed for IgE. Patients were group in either Met/
Met, Met/Val, or the wild type variant Val/Val. Enhanced IgE levels are 
defined >100 U/ml (dashed line). Statistic analysis was performed with 
two‑tailed Chi‑Square/Fisher’s exact test with *p < 0.05 between Met/
Met or Met/Val and the variant Val/Val.
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association of COMT variants with IgG3 and IgG4 levels 
(Fig. 5) nor with IgE levels (not shown) was found.
Discussion
In this study, we analyzed polymorphisms of genes regu-
lating the metabolism of neurotransmitters and cortisol 
in CFS patients. We found no difference in the preva-
lence of the SNPs for COMT rs4680, FKBP5 rs1360780 
and CRHR1 rs12944712 in CFS patients compared to 
controls. However, we observed elevated IgE levels, 
diminished IgG3 levels and an enhanced susceptibility to 
RRTI in patients with the hypofunctional Met variant for 
COMT SNP rs4680. Further, diminished IgG4 levels were 
associated with the wild type allele of the SNP rs1360780 
in comparison to the variant of FKBP5.
First of all, our observation of similar frequency of the 
COMT SNP in CFS patients and controls is in contrast to 
previous reports. A study of Sommerfeldt et  al. showed 
a higher prevalence of the COMT SNP rs4680 in adoles-
cent CFS patients [22]. In contrast, our patients fulfilling 
Fukuda and Canadian criteria were at least 18 years old. 
For our healthy control group, we reached allelic frequen-
cies with 0.59 for the G variant and 0.41 for the A variant 
of the COMT SNP that are comparable to data supplied 
by the NCBI dbSNP Short Genetic Variations Database 
that quote 0.64 for the G and 0.36 for the A variant. 
Another study postulated SNPs for COMT and CRHR1, 
identified by a calculation model, as predictive biomark-
ers for CFS [23]. Restrictively, this analysis included five 
different SNPs for COMT and three SNPs for CRHR1, 
with the SNPs rs4680 and rs13060780 that were analyzed 
in our study not present in the study of Goertzel et al.
A focus in our work was set on the analysis of the 
hypofunctional Met variant of COMT that is linked to 
Table 3 Characteristics of  CFS and  non-CFS patients 
with RRTI
na not applicable.






Age (years) 39 ± 10 42 ± 10 38 ± 13
m/f 37/63 % 35/65 % 29/71 %
Bell score 40 ± 10 30 ± 10 n.a.
RRTI (n) 34 (46 %) 68 (100 %)
Lower RRTI (n) 5 (15 %) 30 (44 %)
 Pneumonia 9 % 19 %
 Bronchitis 15 % 31 %
Upper RRTI (n) 34 (100 %) 54 (79 %)
 Sinusitis 79 % 57 %
 Pharyngitis 15 % 16 %
 Tonsilitis 6 % 10 %
Fig. 4 Distribution of variants for COMT rs4680 in 34 CFS patients with RRTI and 40 CFS patients without RRTI. As control 68 non‑CFS patients with 
RRTI were analysed. Statistic analysis was performed with two‑tailed Chi‑Square/Fisher’s exact test with *p < 0.05 between the variant Met/Met and 
Met/Val, and the major variant Val/Val.
Fig. 5 IgG3 and IgG4 levels in 68 non‑CFS patients with RRTI with 
COMT and FKBP5 SNP. Statistic analysis was performed with the 
Kruskal–Wallis test followed by post hoc testing via two‑tailed Mann–
Whitney U test with Bonferroni adjustment for multiple testing.
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a diminished degradation of catecholamines leading to 
enhanced norepinephrine and cortisol. Enhanced cortisol 
levels were previously shown in healthy subjects with the 
hypofunctional Met/Met variant of COMT rs4680 [33–
35]. In line with this, we observed significantly higher 
cortisol levels in CFS patients with the COMT haplotype 
Met/Met compared to the Val haplotypes. Also polymor-
phisms in FKBP5 and CRHR1, both regulating the cor-
tisol response to stress, were associated with changes in 
HPA axis reactivity [27, 36]. However, in these studies the 
genotypes were not correlated to cortisol or norepineph-
rine levels. No significant difference in cortisol was found 
for FKBP5 and CRHR1 in our patients.
Inflammation is regulated by neuroendocrine hor-
mones including glucocorticoids and catecholamines 
[37]. Immune cells are known to express receptors for 
both cortisol and norepinephrine [38, 39]. In COMT defi-
cient mice minor changes mainly in male animals were 
found with total number of T-, and B-cells and T-cell 
proliferative response decreased, but no impact on NK 
cell cytotoxicity, oxygen radical production and immuno-
globulin production [40]. However, the influence of stress 
and infections on the immune function was not stud-
ied in this model. In a comprehensive study of immune 
parameters in CFS patients we had observed diminished 
immunoglobulin subclass levels in 25 % of CFS patients 
predominantly of IgG3 and IgG4 (Guenther et al. unpub-
lished). Further we found an association of IgG3 defi-
ciency and susceptibility to RRTI. Therefore, we were 
interested to see if there is an association of the COMT 
SNP rs4680 Met variant with immunoglobulin levels and 
RRTI. Lower levels of IgG3 but not of the other immu-
noglobulins were found in CFS patients with the Met 
variant. The half-life of IgG is dependent on the neona-
tal FcRn, which recycles and protects IgG from degrada-
tion. IgG3 has a shorter half-life as the other IgGs which 
is due to the lower affinity of IgG3 to FcRn [41]. Steroids 
decrease FcRn expression and function [42]. Thus, due to 
its shorter half-life IgG3 may be more susceptible to the 
suppressive effects of steroids. We could also observe 
that the Met variant is associated with enhanced sus-
ceptibility to RRTI. Interestingly, we found no enhanced 
frequency of Met alleles in a group of patients with RRTI 
without CFS. One possible explanation for this finding is 
that the dysregulation of cortisol production and immune 
cell sensitivity to steroids described in CFS patients [10, 
17–19] makes CFS patients with the Met variant more 
susceptible to the immunosuppressive effect of cortisol.
In line with our data of lower IgG3 levels in CFS patients 
with the Met/Met genotype of COMT in patients with 
fibromyalgia this COMT variant was shown to be associ-
ated with lower salivary IgA concentration [24]. Further, 
in fibromyalgia enhanced pain sensitivity was reported 
for patients with this COMT variant [43]. No association 
with muscle and joint pain or headache or the Bell score 
was found with the Met variant in our CFS patients.
Further we found that CFS patients with the Met vari-
ant had higher IgE levels. As norepinephrine was shown 
to upregulate the production of IgE [32] the assumed 
stress-related diminished degradation of norepinephrine 
in patients with the Met/Met haplotype may result in 
enhanced IgE levels.
FKBP5 expression is induced by steroids [44, 45] 
and the T variant of rs1360780 was shown to result in 
enhanced negative feed-back of the cortisol response as 
shown in the dexamethasone/CRH test [28]. This SNP 
was found to be associated with increased risk for post-
traumatic stress [46] and depression [47]. We could not 
find a correlation of the FKBP5 SNP with cortisol levels. 
We observed, however, that the wild type C allele of the 
FKBP5 SNP that has lower repressive function and may 
thus result in higher cortisol levels is associated with a 
trend of lower IgG4 levels in our patients.
Limitations of the study are the relatively small sample 
size for a SNP analysis and that clinical parameters were 
evaluated retrospectively.
Conclusion
In conclusion, our data provides evidence for an asso-
ciation of the hypofunctional COMT SNP with immune 
function in CFS. Both enhanced catecholamine and cor-
tisol levels may lead to diminished IgG production.
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